Please assess the completion status of the following clinical trial:

Trial Title: Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-uninfected within 28 days of enrollment~* Meets DSM-IV criteria for opiate dependence~* Positive urine test for opiates~* Injected opiates at least 12 times in the 28 days prior to enrollment, according to self-report~* Willing to use acceptable forms of contraception for the first 12 months of the study~* Able to provide contact information and willing to be contacted by study staff as necessary~* Available for study visits for at least 2 years~Exclusion Criteria:~* Current treatment with methadone, morphine, levo-alpha-acetyl-methadol (LAAM), naltrexone, or nalmefene~* Currently enrolled in another HIV prevention or drug use intervention study~* Known sensitivity to buprenorphine or naloxone~* Requires immediate medical attention for dependence on alcohol, benzodiazepines, or other substances. People who are dependent on tobacco are not excluded.~* Currently injecting drugs of abuse other than opiates, more than twice in the last 28 days, according to self-report~* Psychological disturbance or cognitive impairment that may interfere with the study~* Acute or chronic kidney failure~* Certain abnormal laboratory values~* Any other medical or psychiatric condition that, in the opinion of the investigator, would make participation in this study unsafe~* Pregnant or breastfeeding~Inclusion Criteria for Substudy:~* Current or former participant in HPTN 058 study in Xinjiang who was actively in the long-term treatment arm on stable maintenance dose of Suboxone when detained/arrested (last dose within 2 days of incarceration), resulting in immediate cessation of Suboxone without tapering~* Currently released from detention~* Willing to complete one-time questionnaire~* Willing to sign informed consent~Exclusion Criteria for Substudy:~* Any medical or psychiatric condition that, in the opinion of the investigator, would make participation in the study unsafe, or would otherwise interfere with the study objectives or interpretation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Long term medication assisted treatment (LT-MAT) (Type: EXPERIMENTAL): Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
- Short term medication assisted treatment (ST-MAT) (Type: EXPERIMENTAL): Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).